REGENXBIO Inc.
$9.47
▼
-1.16%
2026-04-21 09:08:01
www.regenxbio.com
NMS: RGNX
Explore REGENXBIO Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$488.82 M
Current Price
$9.47
52W High / Low
$16.19 / $5.85
Stock P/E
—
Book Value
$2.02
Dividend Yield
—
ROCE
-48.13%
ROE
-1.07%
Face Value
—
EPS
$-3.76
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
371
Beta
1.13
Debt / Equity
253.59
Current Ratio
2.38
Quick Ratio
2.38
Forward P/E
-4.01
Price / Sales
2.66
Enterprise Value
$484.64 M
EV / EBITDA
-3.33
EV / Revenue
2.84
Rating
Buy
Target Price
$27.82
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ImageneBio, Inc. | $6 | — | $65.99 M | — | -34.18% | -68.91% | $18 / $3.94 | $11.91 |
| 2. | Moleculin Biotech, Inc. | $2.56 | — | $13.66 M | — | -164.37% | -2.56% | $28.61 / $1.79 | $4.69 |
| 3. | Humacyte, Inc. | $0.69 | — | $157.68 M | — | -110.35% | 164.78% | $2.93 / $0.55 | $0.02 |
| 4. | Cybin D/B/A Helus Pharma | $5.61 | — | $1.92 M | — | -60.35% | -55.89% | $12.7 / $5.9 | $5.49 |
| 5. | Arcellx, Inc. | $115 | — | $6.73 B | — | -50.64% | -53.42% | $115.13 / $47.86 | $6.95 |
| 6. | Polaryx Therapeutics, Inc. | $5.7 | — | $289.74 M | — | -171.33% | -1.94% | $48.91 / $2.2 | $0.1 |
| 7. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 30.34 M | 29.73 M | 21.36 M | 89.01 M | 21.21 M |
| Operating Profit | -57.64 M | -52.41 M | -63.28 M | 12.13 M | -51.37 M |
| Net Profit | -67.15 M | -61.94 M | -70.87 M | 6.08 M | -51.19 M |
| EPS in Rs | -1.3 | -1.2 | -1.37 | 0.12 | -0.99 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 170.44 M | 83.33 M | 90.24 M | 112.72 M |
| Operating Profit | -161.2 M | -231.25 M | -268.13 M | -262.88 M |
| Net Profit | -193.88 M | -227.1 M | -263.49 M | -280.32 M |
| EPS in Rs | -3.76 | -4.4 | -5.11 | -5.43 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 453.03 M | 465.99 M | 573.97 M | 833.27 M |
| Total Liabilities | 350.3 M | 206.34 M | 262.23 M | 317.07 M |
| Equity | 102.73 M | 259.65 M | 311.74 M | 516.2 M |
| Current Assets | 281.28 M | 278 M | 334.97 M | 415.98 M |
| Current Liabilities | 118.09 M | 103.19 M | 130.27 M | 130.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -123.96 M | -173.12 M | -218.41 M | -207.49 M |
| Investing CF | -15.87 M | 103.45 M | 190.94 M | -11.93 M |
| Financing CF | 116.77 M | 92.68 M | -34.97 M | -28.84 M |
| Free CF | -126.38 M | -175.56 M | -228.37 M | -238.21 M |
| Capex | -2.41 M | -2.44 M | -9.96 M | -30.72 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -7.66% | -19.94% | — | — |
| Earnings Growth % | 13.81% | 6% | — | — |
| Profit Margin % | -272.54% | -291.99% | -248.68% | — |
| Operating Margin % | -277.51% | -297.12% | -233.2% | — |
| Gross Margin % | 59.72% | 58.76% | 51.61% | — |
| EBITDA Margin % | -237.89% | -265.36% | -216.67% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.